CAS Number: 129176-97-2
Molecular Weight: 1667.7
Salt Form: TFA
Sequence (3-letter): e-nicotinoyl-D-Lys-Pro-3Pal-Pro-(3,4Cl)D-Phe-Asn-D-Trp-Phe-D-Trp-Leu-Nle-NH2 (3Pal = 3-pyridylalanine)
Sequence (1-letter): (e-nicotinoyl)kP(3Pal)P((3,4Cl)D)FNwFwL(Nle)-NH2
Storage: -20 °C or below
Solubility: water (1 mg/mL)
Spantide II is an undecapeptide substance P (SP) analog that is more potent as a substance P antagonist than spantide I and less effective in releasing histamine from mast cells. It is a neurokinin-1 receptor (NK-1R) antagonist that is used to control inflammation, particularly in skin conditions, and has negligible neurotoxicity.
1. Hakanson, R. et al. (1990) “Spantide II, a novel tachykinin antagonist having high potency and low histamine-releasing effect” Regul. Pept. 31 (1): 75-82.
2.Kincy-Cain, T. and Bost, K.L. (1996) “Increased susceptibility of mice to Salmonella infection following in vivo treatment with the substance P antagonist, spantide II” J. Immunol. 157 (1): 255-264.
3. Gerfen, C.R. (1991) “Substance P (neurokinin-1) receptor mRNA is selectively expressed in cholinergic neurons in the striatum and basal forebrain” Brain Res. 556 (1): 165–170.